Ribociclib and Bicalutamide in AR+ TNBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: ribociclib|DRUG: ribociclib|DRUG: Bicalutamide
Sponsor: Kari Wisinski
Collaborators: Novartis|Big Ten Cancer Research Consortium|University of Wisconsin, Madison